Community Forum : New Practitioner Network
Welcome Guest   
 Subject : FDA Approves Brimonidine as OTC treatment for ocular redness.. 03/02/2018 10:04:28 PM 
Miranda Wilhelm
Posts: 5
In December 2017, the Food and Drug Administration (FDA) approved brimonidine 0.025% ophthalmic solution for the treatment of ocular redness. This is the first over-the-counter eye drop to contain brimonidine.

Brimonidine is an alpha 2 agonist first approved by the FDA in 1996 for the treatment of elevated intraocular pressure (IOP) in patients with glaucoma. The brand name for prescription products containing brimonidine is Alphagan P®.

Brimonidine will join current ophthalmic decongestants for the treatment of ocular redness. These products, such as naphazoline and tetrahydrozoline, work as adrenergic agonists to cause vasoconstriction. Using these products for longer than 3 to 5 days can result in rebound congestion resulting in ocular redness and loss of effectiveness. Brimonidine selectively constricts ocular veins, increasing oxygen availability in the eye and therefore reducing the potential for rebound congestion.

Bausch + Lomb will market the product as Lumify® and it is expected to be available in the second quarter of 2018.
# of Topics per Page